CVRx, Inc. (NASDAQ:CVRX) Stock Rated “Hold” by Wall Street Analysts

Shares of CVRx, Inc. (NASDAQ:CVRX – Get Free Report) have been given a consensus rating of “Hold” by the seven research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $2.70.

A number of research analysts have recently commented on CVRX shares. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research note on Friday, October 30th. Lake Street Capital dropped their price target on CVRx from $3.50 to $1.50 and set a “hold” rating on the stock in a research report on Friday, November 6th. Canaccord Genuity Group downgraded CVRx from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $5.00 to $2.00 in a report on Friday, November 6th. William Blair lowered CVRx from an “outperform” rating to a “market perform” rating in a research report on Friday, November 6th. Finally, Craig Hallum downgraded CVRx from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research note on Friday, August 7th.

Get Our Latest Analysis on CVRx

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. boosted its holdings in CVRx by 148.9% in the third quarter. Goldman Sachs Group Inc. now owns 372,175 shares of the company’s stock worth $651,000 after purchasing an additional 222,666 shares during the last quarter. Jump Financial LLC lifted its holdings in CVRx by 26.0% during the third quarter. Jump Financial LLC now owns 97,673 shares of the company’s stock valued at $171,000 after purchasing an additional 20,173 shares in the last quarter. Empowered Funds LLC purchased a new position in shares of CVRx during the 3rd quarter valued at $63,000. First Eagle Investment Management LLC bought a new position in CVRx in the 3rd quarter worth approximately $386,000. Finally, Russell Investments Group Ltd. grew its position in shares of CVRx by 2,137.6% during the third quarter. Russell Investments Group Ltd. now owns 100,937 shares of the company’s stock valued at $177,000 after purchasing an additional 96,426 shares in the last quarter. 75.27% of the stock is owned by institutional investors.

Key CVRx News

Investors following CVRX have been watching these news items:

  • Negative Sentiment: The lawsuit alleges CVRx misled investors between July 25, 2023, and August 6, 2026. Reports cite alleged kickbacks involving its Barostim heart-failure device and a federal False Claims Act probe, alongside a guidance cut attributed to weak sales-force productivity. These are allegations, not proven findings. Article
  • Negative Sentiment: Several firms reiterated the class action and urged eligible investors to seek lead-plaintiff status by January 8, 2027. Repeated litigation notices may keep legal and reputational risks in focus, though they are largely reminders rather than separate developments. Article

CVRx Stock Down 11.8%

Shares of NASDAQ CVRX opened at $0.53 on Friday. The company has a market cap of $15.18 million, a price-to-earnings ratio of -0.27 and a beta of 0.81. The firm’s fifty day moving average is $1.66 and its 200 day moving average is $4.87. The company has a quick ratio of 5.71, a current ratio of 6.80 and a debt-to-equity ratio of 4.24. CVRx has a 52 week low of $0.53 and a 52 week high of $10.28.

CVRx (NASDAQ:CVRX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.02). CVRx had a negative return on equity of 208.45% and a negative net margin of 88.28%. The business had revenue of $13.83 million during the quarter, compared to analysts’ expectations of $13.93 million. On average, equities research analysts expect that CVRx will post -2.05 earnings per share for the current year.

CVRx Company Profile

(Get Free Report)

CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.

Featured Stories

Analyst Recommendations for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.